title: Intravitreal bevacizumab for the treatment of myopic choroidal neovascularisation in an Asian population.
authors.forename: Boon Kwang
authors.initials: BK
authors.lastname: Loh
authors.forename: Shu Yen
authors.initials: SY
authors.lastname: Lee
authors.forename: Jacob
authors.initials: J
authors.lastname: Cheng
authors.forename: Ian
authors.initials: I
authors.lastname: Yeo
authors.forename: Doric
authors.initials: D
authors.lastname: Wong
authors.forename: Chong Lye
authors.initials: CL
authors.lastname: Ang
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001208:Asia / Q000208:ethnology; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000208:ethnology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000503:physiopathology*; D011446:Prospective Studies; D016896:Treatment Outcome; D014822:Vitreous Body / Q000098:blood supply*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab